A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease
Status:
Completed
Trial end date:
2018-02-27
Target enrollment:
Participant gender:
Summary
AZD0530 is an inhibitor of Src and Abl family kinases1. It has been developed as treatment
for malignancies because these kinases play a role in tumor invasion and proliferation.
However, the Src family kinases (SFKs) are highly expressed in brain and have major effects
on synaptic plasticity2. Moreover, the investigators have recently shown that a specific SFK,
namely Fyn, is aberrantly activated by specific conformations of the Amyloid Beta (Aß)
peptide from Alzheimer's disease (AD). Genetic deletion of Fyn rescues AD deficits in
preclinical models. This clinical trial will test the potential benefit of AZD0530 for
Alzheimer's disease modification.